metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - (neo)adjuvant (NA)
mHNSCC - 1st line (L1)
mHNSCC - L1 - all population 2
mHNSCC - L1 - PDL1 positive 4
mHNSCC - 2nd line (L2)
mHNSCC - L2 - all population 4
mHNSCC - L2 - PDL1 negative 2
mHNSCC - L2 - PDL1 positive 1
hepatocell cancer (HCC) 1

All treatments
immune chekpoint inhibitors
Immune checkpoint association
durvalumab plus tremelimumab

versus all
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs tremelimumab
vs anti-PD-(L)1
vs durvalumab based treatment
vs durvalumab alone

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open